| 货号 | 21461-25mg |
| 描述 | Amuvatinib is a multi-targeted inhibitor of receptor tyrosine kinases that inhibits c-Kit, platelet-derived growth factor receptor α (PDGFRα), and c-Met (IC50s = 10, 40, and 81 nM, respectively).1 It inhibits growth and induces apoptosis in prostate cancer cell lines, with additive effects achieved when combined with erlotinib (Item No. 10483).1 Amuvatinib sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination.2,3,4 |
| 别名 | HPK56;MP470; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Qi, W.,Cooke, L.S.,Stejskal, A., et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 9(142), 1-12 (2009). 2.Padda, S.,Neal, J.W. and Wakelee, H.A. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl.Lung Cancer Res. 1(4), 238-253 (2012). 3.Welsh, J.W.,Mahadevan, D.,Ellsworth, R., et al. The c-Metreceptortyrosine kinaseinhibitor MP470 radiosensitizes glioblastomacells. Radiat. Oncol. 4(69), (2009). 4.Zhao, H.,Luoto, K.R.,Meng, A.X., et al. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother. Oncol. 101(1), 59-65 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 447.5 |
| 分子式 | C23H21N5O3S |
| CAS号 | 850879-09-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |